176 related articles for article (PubMed ID: 36715544)
1. LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma.
Stein BD; Ferrarone JR; Gardner EE; Chang JW; Wu D; Hollstein PE; Liang RJ; Yuan M; Chen Q; Coukos JS; Sindelar M; Ngo B; Gross SS; Shaw RJ; Zhang C; Asara JM; Moellering RE; Varmus H; Cantley LC
Cancer Discov; 2023 Apr; 13(4):1002-1025. PubMed ID: 36715544
[TBL] [Abstract][Full Text] [Related]
2. An LKB1-SIK Axis Suppresses Lung Tumor Growth and Controls Differentiation.
Murray CW; Brady JJ; Tsai MK; Li C; Winters IP; Tang R; Andrejka L; Ma RK; Kunder CA; Chu P; Winslow MM
Cancer Discov; 2019 Nov; 9(11):1590-1605. PubMed ID: 31350327
[TBL] [Abstract][Full Text] [Related]
3.
Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
[No Abstract] [Full Text] [Related]
4. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
5. The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer.
Kim J; Lee HM; Cai F; Ko B; Yang C; Lieu EL; Muhammad N; Rhyne S; Li K; Haloul M; Gu W; Faubert B; Kaushik AK; Cai L; Kasiri S; Marriam U; Nham K; Girard L; Wang H; Sun X; Kim J; Minna JD; Unsal-Kacmaz K; DeBerardinis RJ
Nat Metab; 2020 Dec; 2(12):1401-1412. PubMed ID: 33257855
[TBL] [Abstract][Full Text] [Related]
6. The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC.
Hollstein PE; Eichner LJ; Brun SN; Kamireddy A; Svensson RU; Vera LI; Ross DS; Rymoff TJ; Hutchins A; Galvez HM; Williams AE; Shokhirev MN; Screaton RA; Berdeaux R; Shaw RJ
Cancer Discov; 2019 Nov; 9(11):1606-1627. PubMed ID: 31350328
[TBL] [Abstract][Full Text] [Related]
7. LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.
Kaufman JM; Amann JM; Park K; Arasada RR; Li H; Shyr Y; Carbone DP
J Thorac Oncol; 2014 Jun; 9(6):794-804. PubMed ID: 24828662
[TBL] [Abstract][Full Text] [Related]
8. Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer.
Kitajima S; Ivanova E; Guo S; Yoshida R; Campisi M; Sundararaman SK; Tange S; Mitsuishi Y; Thai TC; Masuda S; Piel BP; Sholl LM; Kirschmeier PT; Paweletz CP; Watanabe H; Yajima M; Barbie DA
Cancer Discov; 2019 Jan; 9(1):34-45. PubMed ID: 30297358
[No Abstract] [Full Text] [Related]
9. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
10. Elevated nuclear localization of glycolytic enzyme TPI1 promotes lung adenocarcinoma and enhances chemoresistance.
Liu P; Sun SJ; Ai YJ; Feng X; Zheng YM; Gao Y; Zhang JY; Zhang L; Sun YP; Xiong Y; Lin M; Yuan HX
Cell Death Dis; 2022 Mar; 13(3):205. PubMed ID: 35246510
[TBL] [Abstract][Full Text] [Related]
11. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.
Liu Y; Marks K; Cowley GS; Carretero J; Liu Q; Nieland TJ; Xu C; Cohoon TJ; Gao P; Zhang Y; Chen Z; Altabef AB; Tchaicha JH; Wang X; Choe S; Driggers EM; Zhang J; Bailey ST; Sharpless NE; Hayes DN; Patel NM; Janne PA; Bardeesy N; Engelman JA; Manning BD; Shaw RJ; Asara JM; Scully R; Kimmelman A; Byers LA; Gibbons DL; Wistuba II; Heymach JV; Kwiatkowski DJ; Kim WY; Kung AL; Gray NS; Root DE; Cantley LC; Wong KK
Cancer Discov; 2013 Aug; 3(8):870-9. PubMed ID: 23715154
[TBL] [Abstract][Full Text] [Related]
12. Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach.
Caiola E; Falcetta F; Giordano S; Marabese M; Garassino MC; Broggini M; Pastorelli R; Brunelli L
J Exp Clin Cancer Res; 2018 Dec; 37(1):302. PubMed ID: 30514331
[TBL] [Abstract][Full Text] [Related]
13. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
Richer AL; Cala JM; O'Brien K; Carson VM; Inge LJ; Whitsett TG
Cancer Res; 2017 Sep; 77(17):4663-4672. PubMed ID: 28652249
[TBL] [Abstract][Full Text] [Related]
14. Targeting adhesion signaling in
Gilbert-Ross M; Konen J; Koo J; Shupe J; Robinson BS; Wiles WG; Huang C; Martin WD; Behera M; Smith GH; Hill CE; Rossi MR; Sica GL; Rupji M; Chen Z; Kowalski J; Kasinski AL; Ramalingam SS; Fu H; Khuri FR; Zhou W; Marcus AI
JCI Insight; 2017 Mar; 2(5):e90487. PubMed ID: 28289710
[TBL] [Abstract][Full Text] [Related]
15. Systemic Analyses of the Expression of TPI1 and Its Associations with Tumor Microenvironment in Lung Adenocarcinoma and Squamous Cell Carcinoma.
Yang X; Ye C; Zheng H; Dai C; Zhu Y
Dis Markers; 2022; 2022():6258268. PubMed ID: 35126788
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
Liu Y; Li Y; Wang X; Liu F; Gao P; Quinn MM; Li F; Merlino AA; Benes C; Liu Q; Gray NS; Wong KK
Cancer Res; 2017 Sep; 77(18):5068-5076. PubMed ID: 28754670
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors.
Bhatt V; Lan T; Wang W; Kong J; Lopes EC; Wang J; Khayati K; Raju A; Rangel M; Lopez E; Hu ZS; Luo X; Su X; Malhotra J; Hu W; Pine SR; White E; Guo JY
Cell Death Dis; 2023 Jan; 14(1):61. PubMed ID: 36702816
[TBL] [Abstract][Full Text] [Related]
18. The level of oncogenic Ras determines the malignant transformation of Lkb1 mutant tissue in vivo.
Rackley B; Seong CS; Kiely E; Parker RE; Rupji M; Dwivedi B; Heddleston JM; Giang W; Anthony N; Chew TL; Gilbert-Ross M
Commun Biol; 2021 Jan; 4(1):142. PubMed ID: 33514834
[TBL] [Abstract][Full Text] [Related]
19. CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells.
Kim J; Hu Z; Cai L; Li K; Choi E; Faubert B; Bezwada D; Rodriguez-Canales J; Villalobos P; Lin YF; Ni M; Huffman KE; Girard L; Byers LA; Unsal-Kacmaz K; Peña CG; Heymach JV; Wauters E; Vansteenkiste J; Castrillon DH; Chen BPC; Wistuba I; Lambrechts D; Xu J; Minna JD; DeBerardinis RJ
Nature; 2017 Jun; 546(7656):168-172. PubMed ID: 28538732
[TBL] [Abstract][Full Text] [Related]
20. YAP promotes malignant progression of Lkb1-deficient lung adenocarcinoma through downstream regulation of survivin.
Zhang W; Gao Y; Li F; Tong X; Ren Y; Han X; Yao S; Long F; Yang Z; Fan H; Zhang L; Ji H
Cancer Res; 2015 Nov; 75(21):4450-7. PubMed ID: 26363011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
